doi: 10.4103/0976-500X.92495.
Iptakalim: A novel multi-utility potassium channel opener
Affiliations
- PMID: 22368410
- PMCID: PMC3284029
- DOI: 10.4103/0976-500X.92495
Item in Clipboard
Iptakalim: A novel multi-utility potassium channel opener
J Pharmacol Pharmacother.
2012 Jan.
No abstract available
Conflict of interest statement
Similar articles
-
Systematic administration of iptakalim, an ATP-sensitive potassium channel opener, prevents rotenone-induced motor and neurochemical alterations in rats.J Neurosci Res. 2005 May 1;80(3):442-9. doi: 10.1002/jnr.20467. J Neurosci Res. 2005. PMID: 15795934
-
Protective effects of iptakalim, a novel ATP-sensitive potassium channel opener, on global cerebral ischemia-evoked insult in gerbils.Acta Pharmacol Sin. 2006 Jun;27(6):665-72. doi: 10.1111/j.1745-7254.2006.00356.x. Acta Pharmacol Sin. 2006. PMID: 16723083
-
Hypoxic pulmonary hypertension (HPH) and iptakalim, a novel ATP-sensitive potassium channel opener targeting smaller arteries in hypertension.Cardiovasc Drug Rev. 2005 Winter;23(4):293-316. doi: 10.1111/j.1527-3466.2005.tb00174.x. Cardiovasc Drug Rev. 2005. PMID: 16614730 Review.
-
Targeting hypertension with a new adenosine triphosphate-sensitive potassium channel opener iptakalim.J Cardiovasc Pharmacol. 2010 Sep;56(3):215-28. doi: 10.1097/FJC.0b013e3181e23e2b. J Cardiovasc Pharmacol. 2010. PMID: 20410832 Review.
-
ATP-sensitive potassium channel opener iptakalim protected against the cytotoxicity of MPP+ on SH-SY5Y cells by decreasing extracellular glutamate level.J Neurochem. 2005 Sep;94(6):1570-9. doi: 10.1111/j.1471-4159.2005.03306.x. Epub 2005 Jul 5. J Neurochem. 2005. PMID: 16000145
Cited by
-
Iptakalim ameliorates hypoxia-impaired human endothelial colony-forming cells proliferation, migration, and angiogenesis via Akt/eNOS pathways.Pulm Circ. 2019 Oct 18;9(3):2045894019875417. doi: 10.1177/2045894019875417. eCollection 2019 Jul-Sep. Pulm Circ. 2019. PMID: 31692706 Free PMC article.
-
The Pharmacology of ATP-Sensitive K+ Channels (KATP).Handb Exp Pharmacol. 2021;267:357-378. doi: 10.1007/164_2021_466. Handb Exp Pharmacol. 2021. PMID: 34247283
-
Kir6.2 knockout aggravates lipopolysaccharide-induced mouse liver injury via enhancing NLRP3 inflammasome activation.J Gastroenterol. 2014 Apr;49(4):727-36. doi: 10.1007/s00535-013-0823-0. Epub 2013 Jun 16. J Gastroenterol. 2014. PMID: 23771404
-
A new antihypertensive drug ameliorate insulin resistance.Acta Pharmacol Sin. 2012 Apr;33(4):429-30. doi: 10.1038/aps.2012.31. Acta Pharmacol Sin. 2012. PMID: 22476059 Free PMC article. No abstract available.
-
ABCC9/SUR2 in the brain: Implications for hippocampal sclerosis of aging and a potential therapeutic target.Ageing Res Rev. 2015 Nov;24(Pt B):111-25. doi: 10.1016/j.arr.2015.07.007. Epub 2015 Jul 28. Ageing Res Rev. 2015. PMID: 26226329 Free PMC article. Review.
References
-
- Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics–2010 update: A report from the American Heart Association. Circulation. 2010;121:e46–e215. - PubMed
-
- Feig PU, Roy S, Cody RJ. Antihypertensive drug development: current challenges and future opportunities. J Am Soc Hypertens. 2010;4:163–73. - PubMed
-
- Zhou F, Wu JY, Yao HH, Ding JH, Hu G. Iptakalim alleviates rotenone-induced degeneration of dopaminergic neurons through inhibiting microglia-mediated neuroinflammation. Neuropsychopharmacology. 2007;32:2570–80. - PubMed
-
- Pan Z, Huang J, Cui W, Long C, Zhang Y, Wang H. Targeting hypertension with a new adenosine triphosphate-sensitive potassium channel opener iptakalim. J Cardiovasc Pharmacol. 2010;56:215–28. - PubMed
-
- Wang H, Xie WP, Wang H, Hu G. Effects of iptakalim on endothelin-1- induced pulmonary hypertension in rats. Chin J Clin Pharmacol Ther. 2005;10:9–14.
LinkOut - more resources
Full Text Sources